Form 4: Pfizer Executive Mikael Dolsten Acquires Stock Appreciation Rights

Mikael Dolsten, President of R&D at Pfizer, acquired stock appreciation rights (SARs) that will be settled in Pfizer common stock.

Summary

• Mikael Dolsten, President of R&D at Pfizer Inc., reported the acquisition of stock appreciation rights (SARs).
• The transaction occurred on February 27, 2024.
• Dolsten acquired 214,880 SARs that will be settled in Pfizer common stock on February 27, 2029, subject to certain vesting requirements.
• He also acquired 189,867 SARs that will be settled in Pfizer common stock on February 27, 2031, also subject to vesting requirements.
• The exercise price for both sets of SARs is $26.89.
• Following the reported transactions, Dolsten directly owns 214,880 and 189,867 derivative securities respectively.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of SARs could be interpreted as a positive sign of the executive's confidence in the company, but it's not a strong indicator.

Positives

• The acquisition of stock appreciation rights by a high-ranking executive like the President of R&D could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth and seventh anniversary of the grant date.

Industry Context

Stock appreciation rights are a common form of executive compensation in the pharmaceutical industry, aligning executive incentives with shareholder value by rewarding increases in the company's stock price.

Comparison to Industry Standards

• Companies like Johnson & Johnson (JNJ) and Merck & Co. (MRK) also utilize stock appreciation rights as part of their executive compensation packages.
• The specific terms and conditions of these SARs, such as vesting schedules and exercise prices, are generally aligned with industry norms for companies of Pfizer's size and complexity.

Stakeholder Impact

• The acquisition of stock appreciation rights by a key executive could positively influence shareholder sentiment.

Key Dates